Supplementary Appendix: Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
收藏DataCite Commons2025-04-04 更新2025-04-16 收录
下载链接：
https://data.mendeley.com/datasets/24zjytjd7z/1
下载链接
链接失效反馈官方服务：
资源简介：
Supplementary materials for the BE BRIGHT 4-Year Efficacy and Safety manuscript, including Plain Language Summary and supplementary methods, tables, and figures.
提供机构：
Mendeley Data
创建时间：
2025-04-04
